Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$121.71 USD

121.71
1,194,644

+2.36 (1.98%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $121.72 +0.01 (0.01%) 5:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

FDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue

by Zacks Equity Research

Zimmer Biomet Holdings, Inc. (ZBH) revealed that the U.S. Food and Drug Administration (FDA) has closed out its 'Warning Letter' related to the company's Zhejiang, China manufacturing facility.

    Zimmer Biomet Rides on Spine Business, Knee Challenges Stay

    by Zacks Equity Research

    On Jun 6, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).

      Zimmer Biomet (ZBH) Beats on Q1 Earnings and Sales Estimates

      by Zacks Equity Research

      Zimmer Biomet has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released.

        Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?

        by Zacks Equity Research

        Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

          Medical Product Stocks' Earnings on Apr 27: ZBH, RMD & More

          by Zacks Equity Research

          Let's take a look at the major Medical products stocks slated to release their Jan-Mar 2017 quarter's reports on Apr 27.

            Will Zimmer Biomet (ZBH) Beat Earnings Estimates in Q1?

            by Zacks Equity Research

            Zimmer Biomet Holdings, Inc. (ZBH) is expected to beat earnings when it reports its first-quarter 2017 financial numbers on Apr 27.

              Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?

              by Zacks Equity Research

              Let's see if Zimmer Biomet Holdings, Inc. (ZBH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                MedTech Long-Term Prospects Impress: Which Stocks to Buy?

                by Zacks Equity Research

                President Trump will finally replace the ACA and implement his own strategy, the nation is clearly divided into "we need" and "don't need" camps.

                  Zimmer Biomet (ZBH): Tops Q4 Earnings Estimates, Meets Sales

                  by Zacks Equity Research

                  Zimmer Biomet (ZBH) has posted mixed results with its earnings surpassing the Zacks Consensus Estimate and revenues in line with the mark.

                    Medical Products Stocks' Earnings on Jan 31: ZBH, TMO, ABC

                    by Zacks Equity Research

                    Let's take a look at the major Medical Product stocks slated to release their earnings results on tomorrow.

                      Zimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?

                      by Zacks Equity Research

                      Zimmer Biomet Holdings, Inc. (ZBH) is expected to report fourth-quarter 2017 financial numbers on Jan 31, before the opening bell.

                        Does Zimmer Biomet Make for a Suitable Value Investment?

                        by Zacks Equity Research

                        The solid Key Value Statistics are likely to make Zimmer Biomet (ZBH) a decent pick for the value investors.

                          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical

                          by Zacks Equity Research

                          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical

                            Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

                            by Zacks Equity Research

                            Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

                              MedTech Sails Through Macro Woes: Stocks in Focus

                              by Zacks Equity Research

                              Mergers & acquisitions, emerging market expansion, positive demographic trends and new product innovation are the vital forces behind the continued uptrend in the sector's performance.

                                MedTech Industry Stock Outlook - December 2016

                                by Zacks Equity Research

                                The Republican win marked a great victory for the entire medical device industry as the likelihood of a permanent repeal of the 2.3% medical device excise tax will come as a big bonus.

                                  MedTech Industry Stock Outlook - Dec. 2015

                                  by Zacks Equity Research

                                  While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.

                                    MedTech Industry Stock Outlook - Dec. 2015

                                    by Zacks Equity Research

                                    While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.

                                      3 MedTech Stocks Poised to Trump Earnings in Q3

                                      by Zacks Equity Research

                                      Positive demographic trends, new product cycles, expansion into emerging markets and widespread consolidation are the key traits for the MedTech sector.

                                        MedTech Industry Stock Outlook - July/Aug 2015

                                        by Zacks Equity Research

                                        Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.

                                          MedTech Industry Stock Outlook - July/Aug 2015

                                          by Zacks Equity Research

                                          Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.

                                            MedTech M&As Continue Regardless of Tax Scenarios

                                            by Zacks Equity Research

                                            MedTech stalwarts are not expected to shy away from hostile acquisition bids this year.